In a phase II trial involving 125 patients with ERBB2 mutations across 21 cancer types, treatment with neratinib, a pan HER2-TKI, provided a 24% response rate among breast cancer patients with ERBB2 S310, L755, V777, G778_P780dup and Y772_A775dup mutations [77]. Here, ERBB2 is linked to breast cancer.